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Abstract: CB13 (1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone)-loaded 
 poly(lactic-co-glycolic acid) nanoparticles (NPs) were produced by nanoprecipitation and tested 
for their in vitro release behavior and in vitro cytotoxicity assays. The effects of several formulation 
parameters such as polymer type, surfactant concentration, and initial drug amount were studied. 
NPs had a particle size 90–300 nm in diameter. Results obtained show that the main influence 
on particle size was the type of polymer employed during the particle production: the greater 
the hydrophobicity, the smaller the particle size. In terms of encapsulation efficiency (%), high 
values were achieved (∼68%–90%) for all formulations prepared due to the poor solubility of 
CB13 in the external aqueous phase. Moreover, an inverse relationship between release rate and 
NP size was found. On the other hand, low molecular weight and low lactide content resulted in a 
less hydrophobic polymer with increased rates of water absorption, hydrolysis, and erosion. NPs 
showed no cytotoxicity and may be considered to be appropriate for drug-delivery purposes.
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Introduction
Nanotechnology has become one of the most intensively studied research areas in recent 
times. Materials at the scale of a nanometer have unique physicochemical properties 
that are due to their small size, surface area, chemical composition, surface structure, 
solubility, and shape.
Over the last several decades, numerous nanocarrier platforms have been studied 
for their use as therapeutic agents, with great enthusiasm, in both academic and indus-
trial applications. These nanocarrier platforms include liposomes, polymer  therapeutic 
conjugates, polymeric micelles, dendrimers, nanoshells, and nucleic acid-based 
nanoparticles (NPs). These polymeric nanocarriers bear great potential for biomedi-
cal applications owing to their biomolecular design and small size, and are known 
to have shown exciting results in preclinical studies demonstrating their potential 
as therapeutic carriers.1 Among the polymeric carriers, poly(lactic-co-glycolic acid) 
(PLGA) has a great potential in applications combining targeting, imaging, diagnostics, 
and therapy.2 Furthermore, as is known, this polymer can easily be hydrolyzed into 
individual monomers (lactic acid or glycolic acid), which are then removed from the 
body via normal metabolic pathways.3
However, low water solubility of these drugs limits their oral bioavailability and 
absorption. There is thus an urgent need for adequate options to deliver these drugs 
to the patient. Although there are diverse strategies (use of cosolvents, salt formation, 
 complexes with cyclodextrins, etc) to solve this problem,4 several  nanotechnology-based 
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drug delivery systems have emerged to increase the bioavail-
ability of numerous drugs that are poorly soluble in water.5,6 
Currently, there are a considerable number of nanobased 
drug-delivery systems being developed by various pharma-
ceutical companies. A comprehensive review of strategies to 
improve the oral bioavailability of this type of drugs can be 
found in Fasinu et al.7
There have been controversial indications as to the extent 
and mechanism of transport of these nanocarriers, but there 
is now no dispute over the fact that particulate uptake does 
take place, especially via the Peyer’s patches M-cells and 
isolated follicles in gut-associated lymphoid tissue, and also 
via the normal enterocytes.8
In this paper, the cannabinoid 1-Naphthalenyl 
[4-(pentyloxy)-1-naphthalenyl]methanone (CB13), which 
acts as a potent agonist at both the CB1 and CB2 receptors, 
is used as a model drug. This compound, in behavioral animal 
models (rat and guinea pig) of chronic pain (neuropathic 
and nociceptive), has been shown to reverse established 
mechanical hyperalgesia after both oral administration and 
local injection into a hind-paw. In behavioral tests for central 
nervous system (CNS) activity in rat, CB13 produced signifi-
cant CNS effects only at doses that were 20-fold higher than 
the oral doses required to reverse hyperalgesia. Thus, these 
data indicate that CB13 produces antihyperalgesic activity 
predominantly via an action on peripheral sensory nerves.9
However, CB13 is highly lipophilic and belongs to the 
class 2 compounds (low solubility and a high permeability) of 
the Biopharmaceutics Classification System, showing a low 
water solubility (∼0.001–0.002 mg/mL).9 As a consequence 
of its poor solubility and dissolution in the gastrointestinal 
fluids, this compound is incompletely absorbed.9 Hence, this 
drug was selected on the basis of its therapeutic interest and 
inadequate physicochemical properties. It is expected that, by 
including CB13 in a PLGA nanocarrier, problems associated 
with low water solubility will disappear. This way, CB13 oral 
viability would be improved.
Hydrophobic drugs are usually encapsulated in biodegrad-
able polymers using one of three methods:  homogenization, 
sonication, or nanoprecipitation. An ideal method would 
produce NPs with the following characteristics: narrow size 
distribution; size in the range 100–1000 nm (with unimodal 
population); capacity for high drug incorporation; controlled 
drug content over a wide range; nontoxic; and relatively 
easily produced.10 The selected preparation method of NPs 
was the nanoprecipitation method, also known as solvent 
displacement method. It is based on interfacial deposition of 
a polymer after displacement of a semipolar solvent, miscible 
with water, from a lipophilic solution. Rapid diffusion of the 
solvent into the aqueous phase results in a decrease in the 
interfacial tension between the two phases, which increases 
the surface area and leads to the formation of small droplets 
of organic solvent, even without any mechanical stirring.11 
Moreover, this method provides high encapsulation efficiency 
(EE) for drugs presenting low water solubility.3
So, the main objectives of the present study were: (1) to 
produce CB13-PLGA loaded NPs using nanoprecipitation 
as the most suitable technique of synthesis; (2) to realize the 
in vitro characterization of the NPs; and (3) to determine the 
in vitro cytotoxicity of NPs and evaluate their safety and 
potential use as nanocarriers for oral drug administration.
Methods
Materials
CB13 was obtained from Tocris Cookson Ltd (Bristol, UK). 
PLGA 50:50 was obtained in different formulations, 
Resomer® RG 502 (molecular weight [Mw]: 12,000; inher-
ent viscosity: 0.24 dL/g), Resomer RG 502H (Mw:12,000; 
inherent viscosity: 0.19 dL/g), Resomer RG 504 (Mw:48,000; 
inherent viscosity: 0.5 dL/g), Resomer RG 504H (Mw: 
48,000; inherent viscosity: 0.53 dL/g) and PLGA 75:25, 
and Resomer RG 752S (Mw: 15.000; inherent viscosity: 
0.24 dL/g), from Boehringer Ingelheim Gmbh (Ingelheim, 
Germany).
The surfactants employed, Span® 60 and Pluronic® F-68, 
were obtained from Sigma-Aldrich (St Louis, MO). Acetone 
PRS was purchased from Panreac Química (Barcelona, 
Spain); propylene glycol (PPG) and glycerol were obtained 
from Acofarma Distribución SA (Barcelona, Spain).
The reversed phase high-performance liquid chroma-
tography (RP-HPLC) analysis was carried out on a Hitachi 
LaChrom® Series HPLC system (D-7000; Hitachi Ltd, Tokyo, 
Japan) equipped with an L-7200 automatic injector, an 
interphase D-7000 and a quaternary pump (model L-7100), 
and DAD UV–VIS detector (model L-7455). A Waters 
Corp Spherisorb ODS2 column (10 µm, 4.6 mm × 250 mm; 
 Milford, MA), kept at 40.0°C ± 0.1°C (Elite LaChrom L-2350 
column oven; Hitachi Ltd), was used in this analysis. Data 
collection and calculation were done by using HSM D-7000 
LaChrom® software (Hitachi, Ltd).
Preparation of CB13-loaded PLGA NPs
The NPs were prepared by the nanoprecipitation method 
with modification.11 Briefly, a weighed amount of PLGA 
was codissolved with Span 60 in acetone to reach a 1.5% 
w/v concentration. Then, 5 mL of such solution was added 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5794
Martín-Banderas et al
International Journal of Nanomedicine 2012:7
dropwise at different rates (30, 15, and 5 mL/min) using a 
syringe pump (Harvard Apparatus Ltd, Edenbridge, UK) 
into 15 mL Pluronic F68 aqueous solution (0.5% w/v) under 
magnetic stirring. The acetone was then evaporated at room 
temperature (RT) for 4 hours.
The particle suspension was centrifuged over a glycerol 
bed (100 µL) at 10,000 rpm for 15 minutes at 4°C to collect 
the NPs. After washing twice, the NPs were resuspended 
in the cryoprotectant solution and then frozen in liquid 
nitrogen and lyophilized (Criodos-50; Telstar Industrial SL, 
Terrassa, Spain), at −80.0°C ± 0.5°C, and 0.057 mbar, to 
obtain a fine powder. All the formulations were prepared 
in triplicate (n = 3).
For CB13-PLGA loaded NPs, the polymer and drug 
were codissolved in acetone at different concentrations 
(6, 10, and 20% w/w).
Characterization methods
The mean diameter and size distribution of CB13 loaded-
PLGA NPs were measured at 25.0°C ± 0.5°C by a laser scatter-
ing technique based on Mie theory (Partica LA-950V2; Horiba 
Ltd, Kyoto, Japan). An aliquot of 1 mL of recently prepared 
particles was diluted in a 12 mL cell.  Measurements were car-
ried out under continuous magnetic agitation. The influences 
of (1) organic phase addition rate into the aqueous phase, 
(2) the type of polymer, and (3) drug loading were studied.
NP aspect and morphology were studied by scanning 
and transmission electron microscopy (SEM and TEM). 
The shape and morphology characteristics of the NPs were 
determined by SEM (XL-30; Royal Philips Electronics, 
Amsterdam, The Netherlands) after coating lyophilized 
samples with a gold thin film. For TEM analysis (CM-10; 
Philips), a sample of lyophilized particles was suspended in 
distilled water. An aliquot of this suspension was dropped 
on a grid and dried at RT.
NPs surface charge was determined by zeta potential (ZP) 
measurements. The ZP of the particles was determined by 
laser Doppler (Zetamaster 300; Malvern Instruments Ltd, 
Malvern, UK). ZP measurements were carried out in triplicate 
after washing the NPs with distilled water at RT. The effects 
of polymer type and drug loading were studied.
Chromatographic conditions
The introduction of new HPLC methods for routine qual-
ity control of pharmaceutical preparations starts with the 
establishment of the optimal measurement conditions and 
provides the maximum relevant information by analyzing 
the experimental data.12–14
The chromatographic conditions15,16 were determined 
using a column C18 (Spherisorb® 5 µm ODS2, 4.6 × 
250 mm Analytical Column; Waters Corp). The mobile phase 
 consisted of two solvents:
•	 Solvent A: acetonitrile:water:acetic acid (75:23.7:1.3 v/v)
•	 Solvent B: acetonitrile
These solvents were maintained in a flow rate of 1.000  mL/min: 
70%:30% (A:B). The mobile phase was filtered through 
a 0.22 µm nitrocellulose-membrane filter (Merck Mil-
lipore, Billerica, MA) and degassed under vacuum prior 
to use. A calibration curve was constructed using standard 
CB13 solutions in acetone. The calibration curve was lin-
ear between 2.5 and 750 µg/mL (y = 17,268 ⋅ x + 19,0397, 
R2 = 0.9900, F = 583.78, P = 3.25 ⋅ 10−3). The limits of detec-
tion and quantification were 0.5 µg/mL and 1.25 µg/mL, 
respectively.
The detection wavelength UV was 230 nm and the injec-
tion volume was 10 µL. The operating temperatures were 
maintained at RT, but the oven was heated at 40°C to favor 
the mobile phase flow through the column.
Determination of Pluronic F68 residuals
The most popular stabilizer for the production of PLGA-
based NPs is poly(vinyl alcohol), which is difficult to remove 
from the NP surface and has been reported to be potentially 
toxic.17,18 In the present work, Pluronic F68 was employed 
to stabilize the NPs and could be considered as a valuable 
alternative to poly(vinyl alcohol) and a promising FDA-
approved surface active agent for clinical use.19
To determine the residual amounts of Pluronic F68 on 
PLGA NPs, 1H-NMR (500 MHz) spectra were recorded 
at 303 K in CDCl
3
, on a Brüker Avance 500 spectrometer 
(Brüker AXS Inc, Madison, WI). Chemical shifts were 
given in ppm, using the residual protonated solvent signal 
as reference.
Differential scanning calorimetry (DSC)
The physical status of CB13 inside the drug-loaded PLGA 
NPs was investigated by DSC. Thermograms of CB13, 
Pluronic F68, PLGA 50:50, and NPs (6% and 20% w/w drug/
polymer) were recorded on a DSC (Setaram 131; Setaram 
Instrumentation, Caluire, France). Samples (5 mg weighed 
to a precision of 0.005 mg, Model CP 225D; Sartorius AG, 
Goettingen, Germany) were placed in aluminum pans, and 
the lids were crimped using a Shimadzu crimper. Thermal 
behavior of the samples was investigated at a scanning 
rate of 10°C/minute covering a temperature range of 
25°C–300°C.
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Stability study of NPs
It is well known that NPs made of hydrolytic degradable 
polymers will degrade over time. The effects of pH and 
temperature have a crucial effect on long-term stability.20 In 
order to evaluate the stability of PLGA NPs, a brief study was 
carried out. Samples of blank and loaded NPs were incubated 
in Milli-Q water, phosphate-buffered saline (PBS) (pH 7.4), 
and Dulbecco’s modified Eagle medium (DMEM) (Sigma-
Aldrich), at 4°C and 37°C. Samples were collected after 
prefixed incubation periods and centrifuged for 5 minutes 
at 4000 rpm in order to precipitate the aggregates. Finally, 
the mean particle size of the remaining nonaggregated NPs 
was determined by laser scattering.21
Freeze-drying process
Freeze-drying is a widely used process for drying and 
improving the stability of various pharmaceutical agents. 
As this process is relatively slow and expensive, it is usually 
only used for products with a high added value, which is the 
case for most types of NPs containing expensive actives, 
such as CB13. The resulting freeze-dried NPs should have 
certain desirable characteristics: the preservation of the initial 
characteristics of the product, short reconstitution time and 
an acceptable suspension, low or unmodified particle size 
distribution of the NPs suspensions, and unchanged activity 
of encapsulated drug.
There are different factors than can affect the final quality 
of the product: formulation, use of cryoprotectant, and the 
storage conditions. Freezing is the first step of freeze-drying 
and generates many stresses. During this step, the liquid 
suspension is cooled, and ice crystals of pure water form – 
the crystallization of ice may exercise a mechanical stress 
on NPs, leading to their destabilization.
In the present work, the use of two commonly employed 
cryoprotectants at different concentrations was evaluated: 
propylene glycol, a low molecular weight  alcohol; and 
mannitol, a sugar. Both were added directly to the NPs 
suspension before freezing with liquid nitrogen. After 
this, NPs were defrosted at RT. To evaluate the effect of 
each cryoprotectant, NP diameters were measured by laser 
scattering.
Determination of drug incorporation
CB13 content of the NPs was assessed directly from the 
extraction of the drug from NPs. The lyophilized NPs (about 
5 mg) were accurately weighed using a high-precision 
 analytical balance (d = 0.01 mg; Model CP 225D; Sartorius). 
Then, 1 mL acetonitrile was added, and the mixture was 
accurately vortexed to dissolve the particles in the organic 
phase. After this, 10 µL of the solution was filtered (Millex® 
GV syringe filter, 0.22 µm; Merck Millipore) and injected 
into the HPLC system for CB13 detection.
The drug content was expressed as EE (%) and drug 
loading (%) following Equations 1 and 2:
EE
Actual amount of CB loaded in NPs
amount of CB in
% = 13
13Theoretical NPs




× 100
 
(1)
Drug loading w w
Massof CB in NPs
Massof NPs re ered
(% / ) = 



×13
cov
100 
(2)
In vitro drug release
NP samples were suspended in phosphate buffer (pH 7.4), 
maintained at 37°C, and stirred mechanically (100 rpm) 
 during the release experiments (Unitronic Vaivén; Selecta 
S.A., Barcelona, Spain). Aliquots (500 µL) were withdrawn 
at fixed time intervals and filtered upon centrifugation at 
8000 rpm. The filtered sample (Millex GV) (10 µL) was 
injected into the HPLC apparatus for the evaluation of 
CB13.
Cell culture and in vitro cytotoxicity
Cytotoxicity assays were realized using human normal colonic 
CCD-18Co cell lines and the human carcinoma T-84 cell lines 
obtained from American Type Culture Collection (ATCC, 
Manassas, VA). CCD-18Co cells were grown in Eagle’s 
minimal essential medium (MEM) (Sigma-Aldrich) with 
Earle’s balanced salt solution (BSS) and supplemented with 
10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM 
sodium pyruvate, and 14 mM NaHCO
3
. T-84 cells were 
grown in DMEM, supplemented with 10% FBS, 2 mM 
L-glutamine, 15 mM HEPES, 14 mM NaHCO
3
. Gentamicin 
(40 µg/mL) and ampicillin (500 µg/mL) (Antibióticos SA, 
Madrid, Spain) were used in both mediums. Cells were 
maintained in monolayer culture at 37°C in an atmosphere 
containing 5% CO
2
. The cytotoxicity of CB13 loaded-PLGA 
NPs (Resomer 502) was evaluated using a proliferation assay; 
a study of blank NPs and free CB13 toxicity was included. 
Cells were seeded in a 24-well plate (25 × 103 cells per 
well) and treated with CB13 loaded-PLGA NPs, blank NPs, 
and free CB13 at a wide range of concentrations. At 24 and 
48 hours, cells were fixed with 10% trichloroacetic acid for 
60 minutes at 4°C and stained with 0.4% sulforhodamine 
B/1% acetic acid by incubating for 10 minutes with 
constant shaking. Cells previously washed with 0.1% 
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acetic acid were left in 10 mM Trizma® (T6066-100G; 
Sigma-Aldrich) for 15 minutes at room temperature with 
constant shaking. The optical density (OD) at 492 nm 
was determined using a Titertek Multiscan MC (Flow 
Laboratories Ltd., Irvine, Ayrshire, Scotland). To determine the 
percentage of relative cell viability (%RCV) we used the formula 
%RCV = (treated cells OD/untreated cells OD) × 100.
Results and Discussion
Characterization of the NPs
The size and size distribution of the NPs was measured by 
laser scattering and the results are reported in Table 1. The 
data are expressed as the mean diameter value and standard 
deviation (SD) obtained from independent experiments.
The analysis showed that the samples had a particle size 
90–300 nm in diameter regardless of the initial conditions in the 
preparation, with a coefficient of variation (CV) about 30%. The 
effect of polymer type, surfactant concentration, and initial drug 
amount were studied. Results obtained showed that the main 
influence on particle size was the type of polymer employed 
during the particle production. It can be seen that for Resomer 
502 and 502H, particles were 300 nm in diameter, and for 504, 
504H, and 752S, particles were around 100 nm in diameter.
The particle size of NPs prepared with Resomers 
decreased with increase in molecular weight from 12,000 to 
48,000 Da (502 vs 504). These results can be explained by the 
hydrophobicity of the polymer employed. At high molecular 
weight, higher hydrophobicity and smaller particle size were 
obtained due to longer aliphatic chains.22,23 No differences 
in size were found due to the presence of terminal carboxyl 
groups in both cases.22 Comparing results obtained for R502 
and R752S (similar molecular weight), smaller diameters 
were obtained when R752S was used. In this case, the lactic 
acid portion increased up to 75%.
The reproducibility of the procedure was also evaluated. 
Interlot CV% was in all cases less than 10%, which points 
to a reliable procedure for NP production.
The ZP values of the NPs shown in Table 1 indicate the 
negative charges on the NP bare surface, which is due to 
the overall negative charges of functional groups on PLGA 
in Milli-Q water. The high negative surface change is an 
important indication for the stability of a colloidal system in 
medium. The repulsion among the highly negatively charged 
NPs provides extra stability. The ZP of four of the types of 
NPs was measured below –24 mV, proving the high stability 
of the NPs suspended in aqueous medium. When CB13-
PLGA NPs were evaluated, a lower ZP value was obtained 
(–20 mV; data not shown).
The use (or not) of a surfactant on the organic phase also 
strongly affected the particle size of NPs elaborated with 
Resomer 502 and 502H (see Table 2). It can be seen that 
when no surfactant was employed or its concentration was 
too low, particle diameter increased up to 600 nm, and there 
was a higher degree of polydispersity.
The initial amount of CB13 was also evaluated. No influ-
ence on particle size or particle size distribution was found 
(see Table 3).
As an example, Figure 1 shows a SEM microphotograph 
of the PLGA NPs. The picture revealed a regular and sym-
metrical morphology, and after processing the SEM image, 
the size of the resulting particles was between 170 and 
230 nm (by laser scattering analysis).
Drug loading
The capacity for drug loading of the NPs is an important 
factor in their formulation since high loading implies smaller 
amounts of the NPs are needed for a given dose of the 
 treatment. The CB13 loading (%w/w) as well as the EE% 
are reported in Table 4.
In terms of EE%, high values were achieved for all 
NPs prepared due to the poor solubility of CB13 in the 
external aqueous phase,24 and highest values were achieved 
using Resomer 502. Panyam et al25 demonstrated that when 
 hydrophobic drugs are used, NPs drug loading is closely 
Table 1 Particle mean diameter, size distribution, and ZP values 
obtained as a function of polymer used (n = 6)
Polymer Dmean  
(nm)
SD  
(nm)
CV (%)  
intralot
CV (%)  
interlot
ZP ± SD  
(mV)
R502 311.02 12.94 34.2782 4.16 −24.5 ± 2.3
R502-H 281.37 11.30 34.628 4.02 −42.6 ± 0.6
R504 89.33 0.96 35.0231 1.08 −28.4 ± 1.1
R504-H 91.97 10.38 34.8708 2.29 −44.8 ± 0.9
R752S 131.06 6.02 38.1749 4.60 −33.2 ± 0.7
Abbreviations: R, Resomer®; Dmean, mean diameter; SD, standard deviation; 
CV (%), coefficient of variation percentage; ZP, zeta potential.
Table 2 Particle mean diameter and size distribution of the nano-
particles as a function of surfactant concentration assayed (n = 3)
Polymer Csurf (%w/v) Dmean (nm) SD (nm) CV (%)
R502 0 592.60 296.10 49.97
0.1 462.26 533.70 115.45
0.5 304.22 111.50 36.65
R502-H 0 600.56 219.89 36.61
0.1 269.40 96.70 35.89
0.5 287.35 116.38 52.22
Abbreviations: R, Resomer; Csurf, surfactant concentration; Dmean, mean diameter; 
SD, standard deviation; CV (%), coefficient of variation percentage.
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Table 3 Size and size distribution of the nanoparticles as a 
function of initial amount of CB13 employed (polymer used: 
Resomer 502) (n = 3)
CB13 (%w/v) Dmean (nm) SD (nm) CV (%)
0 291.28 99.8 34.2782
10 321.73 108.9 33.857
20 315.25 108.3 34.360
Abbreviations: CB13, 1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone; 
Dmean, mean diameter; SD, standard deviation; CV%, coefficient of variation 
percentage.
18
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Figure 1 (A) Typical size distribution for CB13-PLGA NPs (polymer used: Resomer 502, loading: 10% w/w). (B) SEM photograph of the same formulation.
Abbreviations: CB13, 1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone; PLGA, poly(lactic-co-glycolic acid); NPs, nanoparticles; SEM, scanning electron microscope.
matched with the respective solid-state drug–polymer 
 solubility, that is, the ability of the polymeric matrix to entrap 
drug in the dispersed state. The solid-state solubility of the 
drug in the polymer increased with an increase in the lactide 
content in the polymer and with a decrease in the molecular 
weight. Moreover, the presence of free acid end groups in 
the polymer resulted in a decrease in the drug’s solubility in the 
polymer. This can be explained on the basis of the increasing 
hydrophobicity of the polymer with increasing lactide content 
or with ester end groups, resulting in better solid-state solubility 
of the hydrophobic drug in the  hydrophobic polymer matrix.
So, in our study this hypothesis is true. NPs elaborated 
with Resomer 502 showed the highest values in drug load-
ing due to their lower molecular weight and the presence of 
the esterified end groups. On the other hand, NPs elaborated 
with Resomer 504H showed the lowest values due to their 
higher molecular weight and the presence of free acid end 
groups. Finally, NPs elaborated with Resomer 752S showed 
similar drug loading values to those obtained using Resomer 
502, where the effects of molecular weight and lactide content 
would be balanced.
In relation to the initial amount of CB13 employed 
(6, 10, or 20%w/w), EE decreases when CB13 initial con-
centration increases. This means that there is a maximum 
quantity of drug that can be entrapped in the polymer 
matrix in the dispersed state; that is, there is a limit of drug 
miscibility in the polymer.26 The remainder of the drug can 
migrate to the surrounding emulsifier aqueous phase. As 
was indicated by Panyam et al,25 if the surfactant utilized to 
stabilize the emulsion is present at a concentration greater 
than its critical micellar concentration, surfactant micelles 
can solubilize the drug, resulting in a loss of encapsulation 
by the NPs. In our case, the concentration of surfactant-
used, Pluronic F68 (0.06 mM), was slightly above its critical 
micellar concentration (0.04 mM), which may explain this 
phenomenon.
In relation to the CB13 loading (%w/w), this seems to 
increase with the initial amount of drug employed during 
the preparation of the NPs. Several studies showed that drug 
loading can be enhanced by increased initial amount of drug. 
However, EE does not necessarily increase with higher initial 
amount of drug. Once the maximum loading capacity of NPs 
is reached, further increase in initial amount of drug can even 
decrease the EE.27
Differential scanning calorimetry (DSC)
The physical states of the drug in the NPs that could influence 
the in vitro and in vivo release of the drug from the system 
was investigated by DSC.28 Figure 2 shows the DSC ther-
mograms of pure CB13 powder, CB13-loaded PLGA NPs, 
and blank PLGA NPs. Pluronic F68 and PPG thermograms 
were also analyzed.
The melting endothermic peak of pure CB13 appeared 
at 69.55°C (∆H = 64,651 J/g). However, no melting peak 
was detected for both NP formulations. Resomer 502 and 
Pluronic F68 presented endothermic peaks at 45.90°C and 
53.07°C, respectively. A Pluronic F68 peak was not detected 
for NPs. Thus, it can be concluded that CB13 inside the NPs 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5798
Martín-Banderas et al
International Journal of Nanomedicine 2012:7
Table 4 Drug loading and encapsulation efficiency of NPs (n = 6)
Polymer CB13  
(%w/w)initial
EE ± SD (%) CB13 loading ± SD 
(%w/w)
R502 6 89.61 ± 0.25 6.16 ± 1.12
10 82.26 ± 3.73 12.22 ± 6.69
20 70.75 ± 4.82 16.26 ± 0.97
R502H 6 80.74 ± 2.95 4.84 ± 1.12
10 77.094 ± 3.01 6.71 ± 2.30
20 67.709 ± 1.98 15.64 ± 3.01
R504 6 75.44 ± 2.79 16.90 ± 1.10
R504H 6 71.53 ± 3.06 16.11 ± 2.24
R752S 6 83.21 ± 1.57 18.75 ± 3.05
Abbreviations: NPs, nanoparticles; R, Resomer; CB13, 1-Naphthalenyl[4-(pentyloxy)-
1-naphthalenyl]methanone; EE, encapsulation efficiency; SD, standard deviation.
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Abbreviations: DSC, differential scanning calorimetry; CB13, 1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone; PLGA, poly(lactic-co-glycolic acid); NPs, nanoparticles; 
PPG, propylene glycol.
was either in an amorphous, disordered crystalline phase or 
in the solid solute.19,29
Residual amount of Pluronic F68
There are several methods to detect residual amounts of surfac-
tants. One of the most popular is a colorimetric method devel-
oped by Childs,30 employed also to quantify residual amounts 
of Pluronic F68. The colorimetric method is based on the for-
mation of a colored complex between two hydroxyl groups of 
Pluronic F68, Ba2+, and an iodine molecule. Then, the complex 
is evaluated by measuring it  spectrophotometrically at 540 nm.
In the present work, the determination of the residual 
amounts of Pluronic F68 was carried out by 1H NMR spec-
troscopy.31 The 1H NMR spectrum of CB13, PluronicF68, 
Resomer 502, and blank and loaded PLGA NPs are shown 
in Figures 3 and 4.
The cleaned NPs were collected by centrifugation and 
lyophilized. The powder obtained was dissolved in CDCl
3
 
for 1H NMR analysis. The residual Pluronic F68 adsorbed 
onto particles was experimentally estimated according to the 
following equation:31
N mgg
M
M
I
I
PF
PLGA
PF
PLGA
( / ) ( . )
( . . )
=




×=
= −
68 68 1 17
5 35 5 15
87δ
δ
1000,  (3)
in which I
PLGA
 was the peak integral of the –CH groups of 
the lactide unit from Resomer 502 (δ = 5.35–5.15 ppm) 
corresponding to 1 proton; I
PF68
 was the peak integral of 
the –CH
3
 groups of polyethylene oxide unit from Pluronic 
F68 (δ = 1.17 ppm) corresponding to 87 protons; M
PLGA
 was 
the sum of the molecular weights of the lactide and the gly-
colic units in PLGA (130 g/mol); and M
PF68
 was the molecular 
weight of the Pluronic F68 (8350 g/mol).
Additionally, 1H-NMR spectra were analyzed to quantify 
the amounts of CB13 present in NPs, following Equation 4. 
Results were expressed as Q (w/w%):
Q
M
M
I
I
CB
PLGA
CB
PLGA
(%) /( )
( )
=




×=
=
13 13 1 2
5 2
3 100
δ
δ
.
.
 
(4)
where M
CB13
 was the molecular weight of CB13 (368.47 g/mol) 
and M
PLGA
 was the sum of the molecular weights of the lactide 
and the glycolic units in PLGA (130 g/mol). I
CB13
 was the peak 
integral of the –CH
3
 groups (δ = 1.2 ppm) corresponding to 
3 protons and I
PLA
 was the peak integral of the –CH groups 
of the lactide unit (PLA [polylactic acid]) from Resomer 502 
(δ = 5.35–5.15 ppm) corresponding to 1 proton.
These results accorded with HPLC results for CB13 
 loading in Resomer 502 NPs (see Table 4).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5799
Cannabinoid derivate-loaded PLGA nanocarriers for oral administration
International Journal of Nanomedicine 2012:7
10 9 8 7 6 5 4 3 2 1 ppm
3.
01
2.
03
6.
13
1.
99
2.
03
1.
00
3.
03
3.
01
1.
03
1.
00
1.
01
1.
00
1.
01
1.
00
A
B
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
3.
81
1.
92
1.
00
Lacti
O
O
O
O
x yO
*
*
CH3
O
Glico
Figure 3 (Continued)
Freeze-drying
NP integrity after the freezing process in liquid nitrogen 
was studied under different experimental conditions in order 
to determine the optimal concentration of cryoprotectant. 
Cryoprotectants are typically small, highly hydroxylated 
molecules, such as monosaccharides or low molecular 
weight alcohols, that can be added to the suspension prior 
to lyophilization to preserve the morphological integrity of a 
nanomaterial during freeze-drying. We therefore went on to 
explore an optimal concentration of two of these substances, 
propylene glycol and mannitol. The amounts of the cryopro-
tective agent were varied from 0 to 50 w/w%, by dissolving 
the agent directly into the NP suspension immediately prior 
to freeze-drying.
As can be seen in Figure 5, the suspension without cryo-
protectant formed sticky gels during freeze drying. These 
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Figure 3 1H NMR spectrum of the CB13 (A), Resomer 502 (B), and Pluronic F68 (C). 
Abbreviation: CB13, 1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone.
lyophilized gels could not be resuspended in Milli-Q water, 
PBS, nor DMEM under any of the conditions tried (including 
ultrasonic agitation).
The particle size after the freezing process was evalu-
ated measuring mean particle diameter by laser scattering. 
Figure 6 shows the effect of the addition of cryoprotectant 
on NPs size and size distribution.
Results obtained for mannitol, suggested that the optimal 
concentration was not reached and that NP diameters were 
decreasing with increasing mannitol concentration. When 
propylene glycol was used, the amount of 100 µL of pro-
pylene glycol was found to be optimal (NPs diameter and 
CV% were close to initial particle diameter).
NP stability
For a better understanding of the in vitro release profiles, NP 
stability in different incubation media at 37°C was analyzed. 
Conversely, to determine the optimal storage conditions, 
stability studies at 4°C were also carried out. Figure 7 shows 
the NP size distribution at different times in Milli-Q water, 
PBS, and DMEM at 4°C or 37°C.
As reference, the green (and red) line indicates the initial 
particle size (300 ± 102 nm; t = 0 hours). After incubation 
in PBS at 37°C for 6 hours (black line), NP size increased 
to up to 100 µm in diameter. In PBS at 4°C for 6 hours 
(blue line), a bimodal particle size distribution was obtained. 
A small fraction of NPs were up to 100 µm in diameter, 
but the major % was around 700 nm in diameter. These 
results point out a slower degradation of NPs in PBS at 4°C 
vs 37°C. Nevertheless, comparing this result with stability 
in Milli-Q water at 4°C, the result is exactly the contrary. 
A bimodal particle size distribution was obtained, with a 
small fraction of NPs at around 1 µm. In DMEM at 37°C 
incubation, results were similar to those obtained in PBS at 
37°C (data not shown).
In vitro release
The two main release mechanisms associated with drug 
release from PLGA-based delivery systems are diffusion 
and degradation/erosion. The release rate is often said to be 
diffusion controlled initially and degradation/erosion con-
trolled during the final stage of the release period. However, 
many factors influence the rate of drug diffusion and the 
degradation kinetics, for example, polymer–drug interac-
tions, drug–drug interactions, water absorption, and pore 
closure. An extensive review focusing on the mechanisms of 
drug release from PLGA-based delivery systems has been 
realized by Fredenberg et al.32
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The effect of type of polymer on the CB13 release profile 
from NPs is presented in Figure 8. As can be seen, there was 
an inverse relationship between release rate and NP size. This 
has been explained by other authors, such as Berkland et al;33 
they verified that large microspheres degrade more quickly 
than small microspheres, probably because of an increased 
accumulation of the acidic products of polymer hydrolysis 
in large microspheres. Hydrolysis occurring on PLGA-based 
systems (scission of ester bonds and subsequent decrease 
in molecular weight) starts immediately upon contact with 
water. Hydrolysis creates acids, which catalyze hydrolysis. 
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Figure 4 1H NMR spectrum of (A) blank NPs and (B)loaded NPs. 
Abbreviation: NPs, nanoparticles.
Figure 5 SEM image of sticky gels without cryoprotectant. 
Abbreviation: SEM, scanning electron microscopy.
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This autocatalytic process is known to cause faster degrada-
tion at the center of the PLGA matrix than at the surface. This 
effect becomes more pronounced with increasing dimensions 
of the delivery system.32
On the other hand, low molecular weight and low lactide 
content result in a less hydrophobic polymer with increased 
rates of water absorption, hydrolysis, and erosion. Lactic 
acid is more hydrophobic than glycolic acid and, therefore, 
the PLGA copolymer becomes more hydrophobic with 
increase in its lactic acid content:34 CB13 release was faster 
from Resomer 502 (PLA:polyglicolic acid [PGA] = 50:50) 
in comparison with Resomer 752 (PLA:PGA = 75:25).
Drug release can be obviously affected by hydrophobic 
interactions between the drug and the polymer. The inter-
actions between drugs and PLGA delivery systems and 
their impact on release profiles have been widely discussed 
previously.10,35,36 Consequently, the slowest release rate 
of CB13 from NPs obtained with Resomer 752 could be 
 attributed to a favorable hydrophobic interaction between 
the drug and this specific copolymer. So, by increasing the 
polymer hydrophobicity, it is possible to reduce the initial 
burst and to extend the period of release.
The glass-transition temperature of the Resomer polymers 
decreases with decreasing lactide content. Resomer RG 502 
has the weakest interactions with the drug and, therefore, 
this is probably the most important reason for faster drug 
release.37,38
In vitro cytotoxicity assays
Despite the advantages PLGA polymers offer as nanocarriers, 
significant cytotoxicity can be observed at high NP concen-
trations39 or when some surfactants are employed during 
particle synthesis.40 In our study, concentrations assayed 
did not significantly affect cell viability, and this was unaf-
fected by the length of exposure (24–48 hours). Moreover, 
the residual amounts of Pluronic F68 found on NP surfaces 
did not affect cell viability.
As shown in Figure 9, the cytotoxic assay results indi-
cate that there were no significant differences between the 
percentage of relative cell viability in the CCD-18Co and 
T-84 cells treated with CB13 loaded-PLGA NPs or blank NPs 
for 24 and 48 hours and those of the parental cells (100%). 
Thus, NP formulations showed no cytotoxicity and may be 
considered to be appropriate for drug-delivery purposes. In 
addition, assays with a solution of CB13 in acetonitrile at 
different concentrations (80, 100, and 150 µM) showed no 
modulation of CCD-18Co and T-84 cell proliferation (data 
not shown).
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Figure 9 Cytotoxic effect of CB13 loaded-PLGA NPs and blank NPs on human normal colonic CCD-18Co (A), and human carcinoma T-84 (B) cell proliferation.
Notes: Cells were seeded in triplicate onto 96-well plates, treated with each compound at a wide range of concentrations, and cell viability measured by sulforhodamine 
method and presented as percent cell viability in relation to untreated cells (n = 3). 
Abbreviations: CB13, 1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone; NPs, nanoparticles.
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Conclusion
Successful CB13-loaded PLGA NPs were produced using 
the nanoprecipitation method. NPs obtained with different 
types of Resomer showed adequate properties in relation to 
particle size, drug content, in vitro release, and cell culture 
cytotoxicity. Results showed that the main influence on par-
ticle size was the hydrophobicity of the polymer: the higher 
the hydrophobicity, the lower the particle size. In relation to 
drug content, highest values were achieved using Resomer 
502. These results indicate that when hydrophobic drugs are 
used, drug loading is closely matched with the respective 
solid-state drug–polymer solubility; that is, the ability of the 
polymeric matrix to entrap drug in dispersed state. Moreover, 
the cytotoxic assay results indicated that these formulations 
showed no cytotoxicity and initially, may be considered to be 
appropriate for CB13 loaded-nanocarrier delivery purposes.
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